The Effect of Intermittent Rifampicin on Raltegravir
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study seeks to address the question of whether intermittent dosing of rifampicin
influences the pharmacokinetics of raltegravir when co-administered. This study aims to look
at what happens when rifampicin is taken 3 times a week with the standard dose and an
increased dose of raltegravir. This is to find out the best dose of raltegravir to take when
taking rifampicin 3 times a week. The study will be conducted in 18 healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Helen Reynolds
Collaborators:
Liverpool University Hospitals NHS Foundation Trust Royal Liverpool and Broadgreen University Hospitals NHS Trust